AbbVie company Allergan has announced that the Phase III GEMINI 1 and 2 trials of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for treating presbyopia symptoms have met their primary efficacy endpoint.

Presbyopia is a progressive eye condition that decreases the eye’s ability to focus on near objects.

AGN-190584 is an optimised formulation of pilocarpine, a cholinergic muscarinic receptor agonist.

The drug is being analysed as a topical, once-daily drop delivered by a vehicle for the treatment of symptoms associated with presbyopia.

AGN-190584 works through dynamic pupil modulation, an effect where the iris sphincter is contracted to achieve pupil size reduction in an optimal range. Pupil size reduction will result in an increased depth of focus.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

For the trials, a total of 750 patients were enrolled and randomised in a one-to-one ratio to receive AGN-190584 (pilocarpine 1.25%) or vehicle (placebo).

Subjects with presbyopia were administered with AGN-190584 bilaterally, once-daily, for 30 days.

The formulation showed significant near vision gains in both studies and in mesopic (in low light) conditions without a loss of distance vision, meeting the primary endpoint.

Most of the trials’ secondary endpoints were met, including a significant improvement in patient-reported outcomes.

The outcomes were increased vision-related reading ability and reductions in the impact of presbyopia on daily life and use of coping behaviours to manage presbyopia.

AbbVie ophthalmology vice-president, global therapeutic area head Michael Robinson said: “Our research shows that the symptoms associated with presbyopia can significantly impact people’s daily lives.

“The positive results from the GEMINI studies show the potential of this investigational optimised formulation of pilocarpine 1.25% to treat symptoms associated with presbyopia.”

The company plans to submit a New Drug Application to the US Food and Drug Administration (FDA) in the first half of next year. The results of these GEMINI trials will become the basis for the process.